Jake Bauer
Net worth: 5 M $ as of 2026-08-30
Net worth: 5 M $ as of 2026-08-30
Jake Bauer is currently Chairman at Bridgebio Oncology Therapeutics, Inc. and Simcha Therapeutics, Inc. He is an Independent Director at Immunovant, Inc., Enliven Therapeutics, Inc., and Attralus, Inc. He serves as Director at Simcha Therapeutics Holding Co. LLC and Enliven Therapeutics, Inc. He is a Venture Partner at ARCH Venture Partners LLC, GSK Equity Investments Ltd., and SR One Capital Management LP.
Formerly, Mr. Bauer was Director at Phoenix Tissue Repair, Inc. from 2018 to 2022.
He was Independent Director at ARYA Sciences Acquisition Corp.
V from 2021 to 2023 and at ARYA Sciences Acquisition Corp.
II in 2020.
He was VP-Business Operations & Head-Development at Ablexis LLC from 2011 to 2014.
He served as Chief Business Officer at MyoKardia, Inc. from 2018 to 2020.
He worked as Consultant at Bristol Myers Squibb Co. from 2020 to 2021.
He was Management Consultant at Putnam Associates LLC from 2001 to 2005.
He was Principal at Zafgen, Inc., Global Blood Therapeutics, Inc., Royalty Pharma Cayman Partners LP, Endo Health Solutions, Inc., CytomX LLC, Agios Pharmaceuticals, Inc., and Third Rock Ventures LLC from 2007 to 2011.
Education includes an undergraduate degree from Duke University conferred in 2001 and an MBA from Harvard Business School conferred in 2007.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-30 | 87,372 ( 0.12% ) | 5 M $ | 2026-08-30 | |
| 2026-06-29 | 8,339 ( 0% ) | 340 398 $ | 2026-08-30 | |
-.--% | 2026-06-15 | 0 ( -.--% ) | - $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Director/Board Member | 2023-02-22 |
| IMMUNOVANT, INC. | Director/Board Member | 2025-03-31 |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 2021-08-31 |
Simcha Therapeutics Holding Co. LLC
Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Operates as a biotechnology company | Director/Board Member | - |
Simcha Therapeutics, Inc.
Simcha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for cancer | Chairman | 2021-12-31 |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | - |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Private Equity Investor | 2020-12-31 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Director/Board Member | 2021-07-27 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Director/Board Member | 2022-01-18 |
| Companies | Position | End |
|---|---|---|
| ░░░░ ░░░░░░░░ ░░░░░░░░░░░ ░░░░ ░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░ ░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 25 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Endo Health Solutions, Inc.
Endo Health Solutions, Inc. Pharmaceuticals: MajorHealth Technology Manufactures analgesics pharmaceutical products | Health Technology |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Finance |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Royalty Pharma Cayman Partners LP
Royalty Pharma Cayman Partners LP Investment ManagersFinance Functions as a private equity fund | Finance |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
CytomX LLC
CytomX LLC Medical SpecialtiesHealth Technology Develops protein therapeutics and integrated medical diagnostic devices | Health Technology |
Ablexis LLC
Ablexis LLC Packaged SoftwareTechnology Services Develops next-generation platform for antibody drug discovery | Technology Services |
Putnam Associates LLC
Putnam Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides strategic management healthcare consultancy services | Commercial Services |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Simcha Therapeutics Holding Co. LLC
Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Simcha Therapeutics, Inc.
Simcha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for cancer | Health Technology |
Immunovant, Inc.
Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Finance |
ARYA Sciences Acquisition Corp. II
ARYA Sciences Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
ARYA Sciences Acquisition Corp. V
ARYA Sciences Acquisition Corp. V Financial ConglomeratesFinance Operates as a blank check company | Finance |
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions